Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts collectively rate Janux Therapeutics “Moderate Buy”: nine analysts recommend buying, three advise holding and two rate the stock a sell. The average 12-month price target is $37.58, though several firms recently lowered their targets.
• JANX opened at $17.52, with a market capitalization of approximately $1.07 billion and a 52-week range of $12.12 to $35.34. The company’s latest quarterly results missed expectations, reporting a $0.35 loss per share versus a $0.25 consensus loss and revenue of $10.27 million versus $19.07 million expected.
• Institutional investors own 75.39% of the stock, with firms including JPMorgan, AQR and UBS increasing their positions recently. Janux is a clinical-stage biotechnology company developing intratumoral immuno-oncology therapies.

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $37.5833.

JANX has been the subject of several recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday, May 11th. Truist Financial reaffirmed a "buy" rating and set a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday, June 25th. Wedbush cut their target price on shares of Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, May 8th. Finally, Guggenheim decreased their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating for the company in a research note on Friday, August 7th.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $17.52 on Thursday. The stock has a 50-day simple moving average of $15.51 and a two-hundred day simple moving average of $14.58. The firm has a market capitalization of $1.07 billion, a P/E ratio of -10.68 and a beta of 2.50. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million during the quarter, compared to analysts' expectations of $19.07 million. As a group, analysts forecast that Janux Therapeutics will post -1.76 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider directly owned 75,941 shares of the company's stock, valued at $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of JANX. AQR Capital Management LLC raised its holdings in Janux Therapeutics by 71.7% in the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company's stock worth $262,000 after purchasing an additional 4,059 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Janux Therapeutics by 18.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company's stock valued at $583,000 after purchasing an additional 3,393 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Janux Therapeutics by 12.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company's stock valued at $5,033,000 after purchasing an additional 20,657 shares during the period. JPMorgan Chase & Co. increased its position in shares of Janux Therapeutics by 82.9% in the second quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company's stock valued at $5,715,000 after buying an additional 112,116 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Janux Therapeutics by 12.0% in the second quarter. Legal & General Group Plc now owns 47,353 shares of the company's stock valued at $1,094,000 after buying an additional 5,055 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source